Trends in Prescribing of Antiseizure Medications in South Korea: Real-World Evidence for Treated Patients With Epilepsy|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Background and Purpose We investigated the trends in the prescribing of antiseizure medication (ASM) over a 9-year period, and provide real-world data regarding ASM prescriptions of patients with epilepsy in South Korea.
Methods This study used data in the Korean National Health Information Database for the period from 2009 to 2017. We included 18 oral ASMs, which were classified into older and newer ASMs based on them first becoming available on the market before or after 1991, respectively.
The annual trends in ASM prescriptions were plotted over the 9-year study period, and changes in these trends were evaluated as average annual percentage changes (AAPCs) using Poisson regression. Age- and sex-stratified analyses were also conducted.
Results Overall, the proportion of prescriptions involving polytherapy with three or more ASMs increased from 10.08% in 2009 to 10.99% in 2017 (AAPC=0.9%, p<0.001) over the 9-year study period. Among monotherapies, although valproate (VPA) was the most frequently prescribed ASM, the prescription rate of levetiracetam (LEV) steadily increased regardless of age and sex over the study period. The monotherapy prescription trends differed depending on age and sex. In the five most frequently used ASM combination regimens, the prescription rates of VPA/LEV, LEV/oxcarbazepine, and LEV/lamotrigine regimens showed increasing tendencies.
In contrast, prescription rates for all combined regimens of older ASMs declined over time in all age groups.
Conclusions This is the first epidemiological study of the changes in prescription trends for ASM in South Korea based on nationwide data from 2009 to 2017. We found progressive increases in the use of newer ASMs for both monotherapy and duotherapy, and for polytherapy with three or more ASMs over the 9-year study period.

번역하기

참고문헌 (Reference)

1 Kwong KL, "Utilization of antiepileptic drugs in Hong Kong children" 46 : 281-286, 2012

2 Glauser T, "Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes" 54 : 551-563, 2013

3 Yu L, "Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018" 167 : 106448-, 2020

4 Hsieh LP, "Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007 : a population-based national health insurance study" 96 : 81-88, 2011

5 Nicholas JM, "Trends in antiepileptic drug utilisation in UK primary care 1993-2008 : cohort study using the General Practice Research Database" 21 : 466-470, 2012

6 Powell G, "Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016 : a retrospective cohort study using electronic medical records" 9 : e032551-, 2019

7 Cho YS, "Trends in antiepileptic drug prescriptions for childhood epilepsy at a tertiary children’s hospital in Korea, 2001-2012" 17 : 487-496, 2015

8 Chen Z, "Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs : a 30-year longitudinal cohort study" 75 : 279-286, 2018

9 Dörks M, "Treatment of paediatric epilepsy in Germany : antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs" 103 : 45-53, 2013

10 Byun JI, "Treatment of epilepsy in adults : expert opinion in South Korea" 105 : 106942-, 2020